Outcomes of patients undergoing radiation therapy for bladder cancer
Objectives: To review our two institutional experiences regarding the historical referral patterns of bladder cancer patients to receive radiation therapy, characteristics of these referred patients, and their treatment outcomes.
Methods: A retrospective review was performed analyzing patients who underwent radiation therapy for bladder cancer from 2005 to 2015 (n = 69) at two regional referral institutions. The age-adjusted Charlson comorbidity index (AACCI) was calculated for each patient. Patients were divided into three groups: definitive concurrent chemoradiation (CCR), aggressive radiation (AR) alone ≥ 50 Gy, or palliative radiation alone (PR) < 50 Gy. Gastrointestinal (GI) and genitourinary (GU) acute toxicities were recorded.
Results: The median overall AACCI score was 7, which correlates to a two-year expected survival of 55% ± 11%. Thirty-five (50.7%) patients received CCR, 19 (27.5%) received AR, and 15 (21.7%) received PR. Patients presented with hematuria (n = 43, 62%), pain (n = 18, 26%), or obstruction (n = 12, 17%). Of symptomatic patients, treatment improved hematuria in 86%, pain in 75%, and obstruction in 42%. Twenty-two recurrences (32%) were identified at follow-up. Local, regional, and distant recurrences developed in 20%, 14%, and 17% of patients who received CCR. There were two grade 3 GU toxicities and one grade 3 GI toxicity; all grade 3 toxicities were in patients receiving CCR.
Conclusions: Bladder preservation is possible with chemoradiation therapy; however, urologists rarely refer patients for consideration of chemoradiation. The limited patients who are referred for radiation generally have limited life expectancy, significant comorbidities, or have advanced disease amenable only to palliation. Palliative radiation improves symptoms with minimal toxicity.
1. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA: Cancer J. Clin 68: 7-30.
2. Konety BR., Allareddy V, Herr H (2006) Complications after radical cystectomy: analysis of population-based data. Urology 68: 58-64.
3. Donat SM, et al. (2009) Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. European Urology 55: 177-186.
4. Huddart RA, et al. (2010) Life and death of SPARE (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU International 106: 753-755.
5. James ND, et al. (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Medicine 366: 1477-1488.
6. Mak RH, et al. (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32: 3801-3809.
7. Vashistha V, et al. (2017) Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: A systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 97: 1002-1020.
8. Duchesne GM, et al. (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys 47: 379-388.
9. McLaren DB, Morrey D, Mason MD (1997) Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly. Radiotherapy and oncology 43: 171-174.
10. Lacarriere E, et al. (2013) The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery. International Braz J Urol 39: 808-816.
11. Gray PJ, et al. (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. European Urology 63: 823-829.
12. Haque W, et al. (2018) National practice patterns and outcomes for T4b urothelial cancer of the bladder. Clinical genitourinary cancer 16: 42-49.
13. Beddhu S, et al. (2000) A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. American J Med 108: 609-613.
14. Koppie TM, et al. (2008) Age adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 112: 2384-2392.
15. CTCAE Common Terminology Criteria for Adverse Events (CTCAE). National Institutes of Health, National Cancer Institute, Bethesda, Maryland. Cited on May 24, 2018. Available from: https://ctep.cancer.gov.
16. CDC: Smoking & Tobacco Use. Centers for Disease Control, Atlanta, Georgia. Cited on May 24, 2018. Available from: https://www.cdc.gov/tobacco.
17. SEER Cancer Stat Facts. National Institutes of Health, National Cancer Institute, Bethesda, Maryland. Cited on May 24, 2018. Available from: https://seer.cancer.gov/statfacts.
18. NCCN Evidence-Based Cancer Guidelines. Bladder Cancer. V5.2018. https://www.nccn.org/
19. Shipley, W. U., et al. (2002) Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60.1: 62-67.
20. Gestaut, Matthew M., and Gregory P. Swanson. (2017) Long term clinical toxicity of radiation therapy in prostate cancer patients with inflammatory bowel disease. Reports of Practical Oncology & Radiotherapy 22.1: 77-82.
21. Efstathiou J, et al. (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. Journal of Clinical Oncology 27.25: 4055.
22. Zaghloul, Mohamed S. (2012) Bladder cancer and schistosomiasis. Journal of the Egyptian National Cancer Institute 24.4: 151-159.
23. Sabaa, Magdy A., et al. Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations. Vol. 28. No. 1. Elsevier, 2010.
24. Williams, Stephen B., et al. (2018). Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA surgery
25. Chang SS, et al. (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urology 198: 552-559.